-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, REHIA6st3PsbxiAHme2HxLs+tENx2RZCVdiA2Y2f/77mOUNNbyuV9lR3+oj/4gbz +FqzZZQnksvVi74r0iwN+g== 0001230295-06-000247.txt : 20061003 0001230295-06-000247.hdr.sgml : 20061003 20061003141331 ACCESSION NUMBER: 0001230295-06-000247 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20060929 FILED AS OF DATE: 20061003 DATE AS OF CHANGE: 20061003 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SAVIENT PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000722104 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 133033811 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 BUSINESS PHONE: 7324189300 MAIL ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 FORMER COMPANY: FORMER CONFORMED NAME: BIO TECHNOLOGY GENERAL CORP DATE OF NAME CHANGE: 19920703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Simon Lee S CENTRAL INDEX KEY: 0001362764 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15313 FILM NUMBER: 061123676 BUSINESS ADDRESS: BUSINESS PHONE: 617-332-7081 MAIL ADDRESS: STREET 1: 35 OLDHAM ROAD CITY: WEST NEWTON STATE: MA ZIP: 02465 4 1 sim117.xml X0202 4 2006-09-29 0 0000722104 SAVIENT PHARMACEUTICALS INC SVNT 0001362764 Simon Lee S C/O SAVIENT PHARMACEUTICALS, INC ONE TOWER CENTER BLVD., 14TH FLOOR EAST BRUNSWICK NJ 08816 1 0 0 0 Common Stock, $.01 par value per share 2006-09-29 4 A 0 576 6.5100 A 7382.0000 D Option to Purchase Common Stock, $0.01 par value 6.5100 2006-09-29 4 A 0 5000 6.5100 A 2007-09-29 2016-09-29 Common Stock, $.01 par value per share 5000.0000 5000.0000 D These shares were granted pursuant to the Company's 2004 Incentive Plan, which provides for the grant to non-employee directors of that number of shares of Common Stock having an aggregate fair market value on the last business day of each quarter equal to $3,750.00, until he is no longer an Outside Director. On September 29, 2006, the fair market value of the Common Stock, based on the closing price, was $6.51. These options will become fully vested and immediately exercisable on 9/29/2007. By: Beata A. Smith as Attorney-In-Fact for 2006-10-03 -----END PRIVACY-ENHANCED MESSAGE-----